Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.

The bismuth-based quadruple regimen has been applied in Helicobacter pylori rescue therapy worldwide. The non-bismuth-based quadruple therapy or “concomitant therapy” is an alternative option in first-line eradication but has not been used in second-line therapy. Discovering a valid regimen for resc...

Descripción completa

Detalles Bibliográficos
Publicado en:BioMed Research International Vol. 2015; pp. 1 - 7
Autores principales: Jheng, Guang-Hong, Wu, I-Chen, Shih, Hsiang-Yao, Wu, Meng-Chieh, Kuo, Fu-Chen, Hu, Huang-Ming, Liu, Chung-Jung, Hsu, Wen-Hung, Hu, Chi-Tan, Bair, Ming-Jong, Kuo, Chao-Hung, Wu, Deng-Chyang, Hsu, Ping-I
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Wiley-Blackwell 5/18/2015
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109274258&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 109274258
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        23146133
        FT2T
      jtl: BioMed Research International
      issn: 23146133
      maglogo: N
    pubinfo:
      dt: 5/18/2015
      vid: 2015
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        109274258
        109274258
        109274258
        10.1155/2015/163960
        109274258
      ppf: 1
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.
      aug:
        au:
          Jheng, Guang-Hong
          Wu, I-Chen
          Shih, Hsiang-Yao
          Wu, Meng-Chieh
          Kuo, Fu-Chen
          Hu, Huang-Ming
          Liu, Chung-Jung
          Hsu, Wen-Hung
          Hu, Chi-Tan
          Bair, Ming-Jong
          Kuo, Chao-Hung
          Wu, Deng-Chyang
          Hsu, Ping-I
        affil: Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung City 807, Taiwan
      sug:
        subj:
          Helicobacter Infections Drug Therapy
          Bismuth Administration and Dosage
          Human
          Randomized Controlled Trials
          Random Assignment
          Rabeprazole Sodium
          Tetracycline
          Metronidazole
          Amoxicillin
          Taiwan
          Funding Source
          Questionnaires
          Chi Square Test
          T-Tests
          Male
          Female
          Middle Age
          Aged
          Data Analysis Software
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: The bismuth-based quadruple regimen has been applied in Helicobacter pylori rescue therapy worldwide. The non-bismuth-based quadruple therapy or “concomitant therapy” is an alternative option in first-line eradication but has not been used in second-line therapy. Discovering a valid regimen for rescue therapy in bismuth-unavailable countries is important. We conducted a randomized controlled trial to compare the efficacies of the standard quadruple therapy and a modified concomitant regimen. One hundred and twenty-four patients were randomly assigned into two groups: RBTM (rabeprozole 20 mg bid., bismuth subcitrate 120 mg qid, tetracycline 500 mg qid, and metronidazole 250 mg qid) and RATM (rabeprozole 20 mg bid., amoxicillin 1 g bid., tetracycline 500 mg qid, and metronidazole 250 mg qid) for 10 days. The eradication rate of the RBTM and RATM regimen was 92.1% and 90.2%, respectively, in intention-to-treat analysis. Patients in both groups had good compliance (~96%). The overall incidence of adverse events was higher in the RATM group (42.6% versus 22.2%, P=0.02), but only seven patients (11.5%) experienced grades 2-3 events. In conclusion, both regimens had good efficacy, compliance, and acceptable side effects. The 10-day RATM treatment could be an alternative rescue therapy in bismuth-unavailable countries.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N